<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Adc Therapeutics Sa — News on 6ix</title>
<link>https://6ix.com/company/adc-therapeutics-sa</link>
<description>Latest news and press releases for Adc Therapeutics Sa on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Tue, 10 Mar 2026 11:30:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/adc-therapeutics-sa" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835427e78dffbe2df0e14d2.webp</url>
<title>Adc Therapeutics Sa</title>
<link>https://6ix.com/company/adc-therapeutics-sa</link>
</image>
<item>
<title>ADC Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Operational Update</title>
<link>https://6ix.com/company/adc-therapeutics-sa/news/adc-therapeutics-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-operational-update-4</link>
<guid isPermaLink="true">https://6ix.com/company/adc-therapeutics-sa/news/adc-therapeutics-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-operational-update-4</guid>
<pubDate>Tue, 10 Mar 2026 11:30:00 GMT</pubDate>
<description>ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today reported financial results for the fourth quarter and full year ended December 31, 2025, and provided recent operational updates.</description>
</item>
<item>
<title>ADC Therapeutics to Host Fourth Quarter and Full Year 2025 Financial Results Conference Call on March 10, 2026</title>
<link>https://6ix.com/company/adc-therapeutics-sa/news/adc-therapeutics-to-host-fourth-quarter-and-full-year-2025-financial-results-conference-call-on-march-10-2026</link>
<guid isPermaLink="true">https://6ix.com/company/adc-therapeutics-sa/news/adc-therapeutics-to-host-fourth-quarter-and-full-year-2025-financial-results-conference-call-on-march-10-2026</guid>
<pubDate>Tue, 03 Mar 2026 12:15:00 GMT</pubDate>
<description>ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that it will host a conference call and live webcast on Tuesday, March 10, 2026, at 8:30 a.m. EDT to report financial results for the fourth quarter and full year ended December 31, 2025, and provide operational updates.</description>
</item>
<item>
<title>ADC Therapeutics to Participate in March Investor Conferences</title>
<link>https://6ix.com/company/adc-therapeutics-sa/news/adc-therapeutics-to-participate-in-march-investor-conferences</link>
<guid isPermaLink="true">https://6ix.com/company/adc-therapeutics-sa/news/adc-therapeutics-to-participate-in-march-investor-conferences</guid>
<pubDate>Tue, 24 Feb 2026 12:15:00 GMT</pubDate>
<description>ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced participation in upcoming investor conferences in March:</description>
</item>
<item>
<title>ADC Therapeutics Announces Amended HealthCare Royalty Financing Agreement</title>
<link>https://6ix.com/company/adc-therapeutics-sa/news/adc-therapeutics-announces-amended-healthcare-royalty-financing-agreement</link>
<guid isPermaLink="true">https://6ix.com/company/adc-therapeutics-sa/news/adc-therapeutics-announces-amended-healthcare-royalty-financing-agreement</guid>
<pubDate>Mon, 23 Feb 2026 12:15:00 GMT</pubDate>
<description>ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that it has entered into an amendment to its royalty purchase agreement with entities managed by HealthCare Royalty.</description>
</item>
<item>
<title>ADC Therapeutics Makes Grants to New Employees Under Inducement Plan</title>
<link>https://6ix.com/company/adc-therapeutics-sa/news/adc-therapeutics-makes-grants-employees-210500991</link>
<guid isPermaLink="true">https://6ix.com/company/adc-therapeutics-sa/news/adc-therapeutics-makes-grants-employees-210500991</guid>
<pubDate>Mon, 02 Feb 2026 21:05:00 GMT</pubDate>
<description>ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that the Company has made grants of options to purchase an aggregate of 308,000 of the Company's common shares to seven new employees on February 2, 2026 (each, a "Grant").</description>
</item>
<item>
<title>ADC Therapeutics Provides Preliminary Fourth Quarter and Full Year 2025 Revenue and Cash Estimates and Recent Corporate Updates</title>
<link>https://6ix.com/company/adc-therapeutics-sa/news/adc-therapeutics-provides-preliminary-fourth-210500572</link>
<guid isPermaLink="true">https://6ix.com/company/adc-therapeutics-sa/news/adc-therapeutics-provides-preliminary-fourth-210500572</guid>
<pubDate>Thu, 08 Jan 2026 21:05:00 GMT</pubDate>
<description>ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today provided corporate updates and highlights from its ZYNLONTA® clinical program.</description>
</item>
<item>
<title>ADC Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference</title>
<link>https://6ix.com/company/adc-therapeutics-sa/news/adc-therapeutics-participate-44th-annual-121500088</link>
<guid isPermaLink="true">https://6ix.com/company/adc-therapeutics-sa/news/adc-therapeutics-participate-44th-annual-121500088</guid>
<pubDate>Thu, 08 Jan 2026 12:15:00 GMT</pubDate>
<description>ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that Ameet Mallik, Chief Executive Officer, will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, CA, on Thursday, January 15, 2026, at 10:30 a.m. PT.</description>
</item>
<item>
<title>ADC Therapeutics Announces New Employee Inducement Grant</title>
<link>https://6ix.com/company/adc-therapeutics-sa/news/adc-therapeutics-announces-employee-inducement-210500842</link>
<guid isPermaLink="true">https://6ix.com/company/adc-therapeutics-sa/news/adc-therapeutics-announces-employee-inducement-210500842</guid>
<pubDate>Fri, 02 Jan 2026 21:05:00 GMT</pubDate>
<description>ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that the Company has made a grant of options to purchase an aggregate of 6,000 of the Company's common shares to a new employee on January 2, 2026 ("Grant").</description>
</item>
<item>
<title>ADC Therapeutics Announces Updated Data from LOTIS-7 Phase 1b Clinical Trial of ZYNLONTA® in Combination with Bispecific Antibody Supporting Potential Best-in-Class Regimen in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma</title>
<link>https://6ix.com/company/adc-therapeutics-sa/news/adc-therapeutics-announces-updated-data-123000435</link>
<guid isPermaLink="true">https://6ix.com/company/adc-therapeutics-sa/news/adc-therapeutics-announces-updated-data-123000435</guid>
<pubDate>Wed, 03 Dec 2025 12:30:00 GMT</pubDate>
<description>ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced updated data from the LOTIS-7 Phase 1b open-label clinical trial evaluating the safety and efficacy of ZYNLONTA® in combination with the bispecific antibody glofitamab (COLUMVI®) in patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL). The updated data is based on investigator assessment and reflects the 49 efficacy-evaluable pa</description>
</item>
<item>
<title>ADC Therapeutics to Provide Update on LOTIS-7 Clinical Trial</title>
<link>https://6ix.com/company/adc-therapeutics-sa/news/adc-therapeutics-lotis-7-clinical-210500194</link>
<guid isPermaLink="true">https://6ix.com/company/adc-therapeutics-sa/news/adc-therapeutics-lotis-7-clinical-210500194</guid>
<pubDate>Tue, 02 Dec 2025 21:05:00 GMT</pubDate>
<description>ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that it will host a conference call and live webcast on Wednesday, December 3, 2025, at 8:00 a.m. EST to provide an update on the LOTIS-7 Phase 1b open-label clinical trial evaluating the safety and efficacy of ZYNLONTA® in combination with the bispecific antibody glofitamab (COLUMVI®) in patients with relapsed or refractory diffuse large B-cell lymphoma</description>
</item>
<item>
<title>ADC Therapeutics Reports Third Quarter 2025 Financial Results and Provides Operational Update</title>
<link>https://6ix.com/company/adc-therapeutics-sa/news/adc-therapeutics-reports-third-quarter-123000670</link>
<guid isPermaLink="true">https://6ix.com/company/adc-therapeutics-sa/news/adc-therapeutics-reports-third-quarter-123000670</guid>
<pubDate>Mon, 10 Nov 2025 12:30:00 GMT</pubDate>
<description>ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today reported financial results for the third quarter ended September 30, 2025, and provided operational updates.</description>
</item>
<item>
<title>ADC Therapeutics to Host Third Quarter 2025 Financial Results Conference Call on November 10, 2025</title>
<link>https://6ix.com/company/adc-therapeutics-sa/news/adc-therapeutics-host-third-quarter-121500089</link>
<guid isPermaLink="true">https://6ix.com/company/adc-therapeutics-sa/news/adc-therapeutics-host-third-quarter-121500089</guid>
<pubDate>Mon, 03 Nov 2025 12:15:00 GMT</pubDate>
<description>ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that it will host a conference call and live webcast on Monday, November 10, 2025, at 8:30 a.m. EST to report financial results for the third quarter of 2025 and provide operational updates.</description>
</item>
<item>
<title>ADC Therapeutics to Present at November Investor Conferences</title>
<link>https://6ix.com/company/adc-therapeutics-sa/news/adc-therapeutics-present-november-investor-111500938</link>
<guid isPermaLink="true">https://6ix.com/company/adc-therapeutics-sa/news/adc-therapeutics-present-november-investor-111500938</guid>
<pubDate>Mon, 27 Oct 2025 11:15:00 GMT</pubDate>
<description>ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced participation in three upcoming investor conferences in November:</description>
</item>
<item>
<title>ADC Therapeutics Announces $60 Million Private Placement</title>
<link>https://6ix.com/company/adc-therapeutics-sa/news/adc-therapeutics-announces-60-million-113000441</link>
<guid isPermaLink="true">https://6ix.com/company/adc-therapeutics-sa/news/adc-therapeutics-announces-60-million-113000441</guid>
<pubDate>Mon, 13 Oct 2025 11:30:00 GMT</pubDate>
<description>ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that it has entered into securities purchase agreements for the sale of its equity securities to certain institutional investors in a $60.0 million private investment in public equity ("PIPE") financing. In the PIPE, ADC Therapeutics is selling 11.3 million common shares at $4.00 per share and pre-funded warrants to purchase 3.8 million common shares at</description>
</item>
<item>
<title>ADC Therapeutics to Present at the Cantor Global Healthcare Conference 2025</title>
<link>https://6ix.com/company/adc-therapeutics-sa/news/adc-therapeutics-present-cantor-global-111500602</link>
<guid isPermaLink="true">https://6ix.com/company/adc-therapeutics-sa/news/adc-therapeutics-present-cantor-global-111500602</guid>
<pubDate>Wed, 27 Aug 2025 11:15:00 GMT</pubDate>
<description>ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that Ameet Mallik, Chief Executive Officer, will participate in a fireside chat at the Cantor Global Healthcare Conference 2025 on Wednesday, September 3, 2025, at 9:10 a.m. ET.</description>
</item>
<item>
<title>ADC Therapeutics Reports Second Quarter 2025 Financial Results and Provides Operational Update</title>
<link>https://6ix.com/company/adc-therapeutics-sa/news/adc-therapeutics-reports-second-quarter-113000533</link>
<guid isPermaLink="true">https://6ix.com/company/adc-therapeutics-sa/news/adc-therapeutics-reports-second-quarter-113000533</guid>
<pubDate>Tue, 12 Aug 2025 11:30:00 GMT</pubDate>
<description>ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today reported financial results for the second quarter ended June 30, 2025, and provided operational updates.</description>
</item>
<item>
<title>ADC Therapeutics to Host Second Quarter 2025 Financial Results Conference Call on August 12, 2025</title>
<link>https://6ix.com/company/adc-therapeutics-sa/news/adc-therapeutics-host-second-quarter-200500120</link>
<guid isPermaLink="true">https://6ix.com/company/adc-therapeutics-sa/news/adc-therapeutics-host-second-quarter-200500120</guid>
<pubDate>Tue, 05 Aug 2025 20:05:00 GMT</pubDate>
<description>ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that it will host a conference call and live webcast on Tuesday, August 12, 2025, at 8:30 a.m. EDT to report financial results for the second quarter of 2025 and provide operational updates.</description>
</item>
<item>
<title>ADC Therapeutics Makes Grant to New Employee Under Inducement Plan</title>
<link>https://6ix.com/company/adc-therapeutics-sa/news/adc-therapeutics-makes-grant-employee-200500859</link>
<guid isPermaLink="true">https://6ix.com/company/adc-therapeutics-sa/news/adc-therapeutics-makes-grant-employee-200500859</guid>
<pubDate>Tue, 01 Jul 2025 20:05:00 GMT</pubDate>
<description>ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that the Company has made grants of options to purchase an aggregate of 17,000 of the Company's common shares to one new employee on July 1, 2025 (each, a "Grant").</description>
</item>
<item>
<title>ADC Therapeutics Announces Updated ZYNLONTA® Investigator-Initiated Trial Data in R/R Marginal Zone Lymphoma Presented at 18th International Conference on Malignant Lymphoma (ICML)</title>
<link>https://6ix.com/company/adc-therapeutics-sa/news/adc-therapeutics-announces-updated-zynlonta-111500037</link>
<guid isPermaLink="true">https://6ix.com/company/adc-therapeutics-sa/news/adc-therapeutics-announces-updated-zynlonta-111500037</guid>
<pubDate>Mon, 16 Jun 2025 11:15:00 GMT</pubDate>
<description>ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced updated data from a Phase 2 multicenter investigator-initiated trial (IIT) of ZYNLONTA® to treat relapsed/refractory marginal zone lymphoma (r/r MZL) will be presented during a poster session at the 18th International Conference on Malignant Lymphoma (ICML) in Lugano, Switzerland on Friday, June 20. These data will be made available online beginning on W</description>
</item>
<item>
<title>ADC Therapeutics Announces $100 Million Private Placement Extending Expected Cash Runway into 2028</title>
<link>https://6ix.com/company/adc-therapeutics-sa/news/adc-therapeutics-announces-100-million-104500398</link>
<guid isPermaLink="true">https://6ix.com/company/adc-therapeutics-sa/news/adc-therapeutics-announces-100-million-104500398</guid>
<pubDate>Thu, 12 Jun 2025 10:45:00 GMT</pubDate>
<description>ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that it has entered into securities purchase agreements for the sale of its equity securities to certain institutional investors in a $100.0 million private investment in public equity ("PIPE") financing. In the PIPE, ADC Therapeutics is selling 13.0 million common shares at $3.53 per share and pre-funded warrants to purchase 15.7 million common shares a</description>
</item>
</channel>
</rss>